Genentech advanced the collaboration's first neuroscience target into a joint early discovery program, providing early ...

AI-native drug discovery advances neuroscience target with Roche while cutting cash guidance.

Recursion Pharmaceuticals' partnerships, notably with Genentech/Roche and Sanofi, have delivered $500M+ in milestone payments ...

Market open and close ceremonies take place daily at the Nasdaq MarketSite Studio in Times Square and around the globe. Executives from Recursion (Nasdaq: RXRX), a leading clinical stage TechBio ...

Roche Holding AG advanced the first project from its AI drug-discovery partnership with Recursion Pharmaceuticals, marking an ...

In the latest trading session, Recursion Pharmaceuticals (RXRX) closed at $2.97, marking a -2.62% move from the previous day. This move lagged the S&P 500's daily loss of 1.52%. On the other hand, the ...

AM ET / 6:00 AM MT / 1:00 PM BST. The company will broadcast the live stream from Recursion’s X, LinkedIn, and YouTube accounts. Investors, analysts, and the public will be able to ask questions of ...

Recursion Pharmaceuticals (NASDAQ:RXRX) outlined progress across its clinical pipeline, drug-discovery partnerships and ...

Recursion Pharmaceuticals (RXRX) closed at $3.01 in the latest trading session, marking a +1.69% move from the prior day. The stock outpaced the S&P 500's daily gain of 0.02%. Elsewhere, the Dow saw ...

Recursion Pharmaceuticals shares have been a disaster for investors who've been holding them. After falling by more than half in less than a year, though, the stock could be a bargain now. Here's a ...

We are no longer just discussing the potential of our platform." (CEO, President & Director Najat Khan) "We now have 5 clinical stage programs, including REC-4881 in FAP, where we have generated some ...